Blood test for hepatitis B liver cancer response to radiation
Part of Cancer, Digestive system, Infections clinical trials.
This study looks at a blood test (biomarker) to see how well people with hepatitis B-related liver cancer respond to radiation therapy and what their long-term outlook may be. It aims to find better ways to predict treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC)
- You test positive for hepatitis B surface antigen (HBsAg)
- Your liver function is at Child-Pugh class A or B (not severely impaired)
- Radiation therapy is the main treatment for your liver tumor
- You have not had radiation therapy to the liver area before
- You are 18 years old or older
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how radiation therapy affects the immune system and outcomes in people with liver cancer. It may help doctors understand better ways to treat the disease.
This study looks at whether certain fats in your blood can help predict how well radiotherapy works for liver cancer. If you are getting radiation for liver cancer, your blood samples may help doctors learn more about your treatment response.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
This study looks at a simple blood test to help predict how well your tumor will respond to radiation therapy. By measuring a protein called CHI3L1 in your blood before and during treatment, the study aims to help doctors personalize your care.
This study looks at blood tests to see if they can predict how well liver cancer responds to a procedure called TACE. Participation involves giving blood samples and having your normal follow-up scans.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.